Senseonics, which has developed the implantable continuous glucose monitoring (CGM) system called Eversense, is teaming-up with Diasend to allow clinical review of patients’ glucose data using the Diasend Clinic and Diasend Personal solutions. The two companies will work together to enable clinicians and patients to utilize the Diasend solution to review past Eversense CGM data along with insulin pump and activity tracker data.

“Senseonics is extremely pleased to be working with a partner as valuable as Diasend, a company that is already well-known and trusted by the diabetes community, to allow users to have access to additional historical data and a more comprehensive data management solution,” Dr. Tim Goodnow, CEO and President of Senseonics, said in a statement.

Eversense is a pill-sized sensor that is entirely implanted in the user’s upper arm from where it can continuously monitor their glucose levels. The device is meant to last at least 90 days before it needs to be replaced. Once implanted, the sensor sends data to a transmitter device that is worn on the upper arm from where the information is relayed to a smartphone or tablet.

On the other hand, Diasend’s solution is currently used in over 2,500 clinics, by more than 130,000 patients every month across the world, according to the company’s CEO and Founder, Anders Sonesson.

“By providing the Eversense CGM’s 90-day data along with other devices in familiar looking reports, we will contribute to a consistent analysis that is optimal for both healthcare professionals in the clinic environment and for a person with diabetes in a home setting via the Diasend Mobile app or web application,” Sonesson said.

Both companies expect to initially target the European market for the integrated Eversense and Diasend solution.